Canine medium macronucleated cell/marginal lymphomas (MZL) are indolent lymphomas arising from the marginal zone of B-cell follicles. The aim of this retrospective study is to gain informations about clinical features, treatments’ options and outcome of dogs with MZL. Materials and Methods: 16 dogs with a cytological/ histopathological diagnosis of MZL. Clinical, laboratory and follow-up data were collected. Results. The splenic form predominated (50.0%, 8 cases), followed by nodal (31.2%, 5 cases) and disseminated (18.8%, 3 cases) subtypes. The great majority of dogs had stage IV disease (62.5%). Among splenic MZL, 4 dogs underwent splenectomy and adjuvant chemotherapy, 3 dogs were treated by means of chemotherapy, and 1 dog underwent surgery only. The 3 longest survivals were recorded in dogs with splenic MZL treated by means of surgery and adjuvant chemotherapy. All dogs with nodal MZL were treated with systemic chemotherapy; 4 (80.0%) achieved complete remission and 1 partial remission. Two out of the 3 dogs with disseminated MZL had the shortest survival. During the disease course, 2 (12.5%) dogs transformed into high-grade centroblastic lymphoma. Median survival for all dogs was 549 days. Conclusions and clinical importance. Anatomic origin of MZL may delineate tumors with distinct biological behavior in dogs. Splenic MZL appears indolent and may benefit from splenectomy, possibly followed by systemic chemotherapy. Nodal and disseminated MZL seems to be clinically aggressive, possibly requiring dose-intense chemotherapeutic strategies.
Canine macronucleated cell/marginal zone lymphoma : description of 16 cases (2001-2008) / P. Valenti, E. Zini, D. Stefanello, S. Comazzi, L. Marconato. ((Intervento presentato al convegno ESVONC annual congress tenutosi a Torino nel 2010.
Canine macronucleated cell/marginal zone lymphoma : description of 16 cases (2001-2008)
D. Stefanello;S. ComazziPenultimo
;
2011
Abstract
Canine medium macronucleated cell/marginal lymphomas (MZL) are indolent lymphomas arising from the marginal zone of B-cell follicles. The aim of this retrospective study is to gain informations about clinical features, treatments’ options and outcome of dogs with MZL. Materials and Methods: 16 dogs with a cytological/ histopathological diagnosis of MZL. Clinical, laboratory and follow-up data were collected. Results. The splenic form predominated (50.0%, 8 cases), followed by nodal (31.2%, 5 cases) and disseminated (18.8%, 3 cases) subtypes. The great majority of dogs had stage IV disease (62.5%). Among splenic MZL, 4 dogs underwent splenectomy and adjuvant chemotherapy, 3 dogs were treated by means of chemotherapy, and 1 dog underwent surgery only. The 3 longest survivals were recorded in dogs with splenic MZL treated by means of surgery and adjuvant chemotherapy. All dogs with nodal MZL were treated with systemic chemotherapy; 4 (80.0%) achieved complete remission and 1 partial remission. Two out of the 3 dogs with disseminated MZL had the shortest survival. During the disease course, 2 (12.5%) dogs transformed into high-grade centroblastic lymphoma. Median survival for all dogs was 549 days. Conclusions and clinical importance. Anatomic origin of MZL may delineate tumors with distinct biological behavior in dogs. Splenic MZL appears indolent and may benefit from splenectomy, possibly followed by systemic chemotherapy. Nodal and disseminated MZL seems to be clinically aggressive, possibly requiring dose-intense chemotherapeutic strategies.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.